Novartis CEO takes pay cut as AbbVie's Rick Gonzalez nabs nearly 10% raise
Two CEOs are looking at noticeably different compensation packages this year when compared to last year.
Novartis CEO Vas Narasimhan, who recently took over as chair of the PhRMA board, last year brought home 8.4 million Swiss francs ($9 million), which was a 25% decrease from a year prior, when he collected 11.2 million Swiss francs ($12 million).
AbbVie CEO Rick Gonzalez, on the other hand, who saw his company exit PhRMA and other industry trade groups in 2022, capped his final year of the company’s monumental Humira monopoly, and earned a raise to $26.2 million in compensation, up from $23.9 million in 2021 and $24 million in 2020.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters